Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of WD-910 in Healthy Participants

NCT06897813 is registered in ClinicalTrials.gov with Zhejiang Wenda Pharma Technology LTD. as lead sponsor.

NCT NCT06897813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06897813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of WD-910 in Healthy Participants
Lead sponsor
Zhejiang Wenda Pharma Technology LTD.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
June 30, 2025
Completion date
December 31, 2025
Enrollment
68 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants